In addition, in our and other studies, we found that Meloxicam not only targets COX-2, but also targets other signaling pathways, including MAPKs [28], NF-κB [29], Wnt/β-catenin, and PI3K/ATK [30] signaling pathways, all of which are associated with the development of cancer and CVD. This evidence concerns the gene NFKB1 and cancer.